Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors

作者：Berghoff A S; Bago Horvath Z; Ilhan Mutlu A; Magerle M; Dieckmann K; Marosi C; Birner P; Widhalm G; Steger G G; Zielinski C C; Bartsch R; Preusser M^*

来源：British Journal of Cancer, 2012, 107(9): 1454-1458.

DOI：10.1038/bjc.2012.440

• metastatic breast cancer
• brain metastases
• brain-only metastatic behaviour
• prognosis
• overall survival
• breast cancer subtypes

BACKGROUND: The clinical course of breast cancer patients with brain metastases (BM) as only metastatic site (brain-only metastatic breast cancer (BO-MBC)) has been insufficiently explored. %26lt;br%26gt;METHODS: All breast cancer patients with BM treated at our institution between 1990 and 2011 were identified. For each patient, full information on follow-up and administered therapies was mandatory for inclusion. Oestrogen receptor, progesterone receptor and Her2 status were determined according to standard protocols. Statistical analyses including computation of survival probabilities was performed. %26lt;br%26gt;RESULTS: In total, 222 female patients (26% luminal; 47% Her2; 27% triple negative) with BM of MBC were included in this study. In all, 38/222 (17%) BM patients did not develop extracranial metastases (ECM) during their disease course and were classified as BO-MBC. Brain-only-MBC was not associated with breast cancer subtype or number of BM. The median overall survival of BO-MBC patients was 11 months (range 0-69) and was significantly longer than in patients with BM and ECM (6 months, range 0-104; P = 0.007). In all, 7/38 (18%) BO-MBC patients had long-term survival of %26gt; 3 years after diagnosis of BM and long-term survival was significantly more common in BO-MBC patients as compared with BM patients with ECM (P%26lt;0.001). %26lt;br%26gt;CONCLUSIONS: Brain-only metastatic behaviour occurs in around 17% of breast cancer with BM and is not associated with breast cancer subtype. Exploitation of all multimodal treatment options is warranted in BO-MBC patients, as these patients have favourable prognosis and long-term survival is not uncommon. British Journal of Cancer (2012) 107, 1454-1458. doi:10.1038/bjc.2012.440 www.bjcancer.

• 出版日期2012-10-23